Status In progress
Process CDF Review
ID number 1583

Provisional Schedule

Final appraisal document 03 April 2020 - 23 April 2020
Expected publication 13 May 2020

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Roche
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health and Social Services and Public Safety, Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
25 February 2020 Committee meeting: 1
17 October 2019 Invitation to participate
30 August 2019 In progress, Obinutuzumab in combination with bendamustine within its marketing authorisation for treating follicular lymphoma that is refractory to rituximab or a rituximab-containing regimen.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance